The Chinese Breast Cancer Treatment Guidelines [4] recommend NAT, particularly for HER2-positive (HER2+) BC or TNBC with specific tumor loads, to gain in vivo drug sensitivity information, optimize post-surgery drug selection, and enhance overall prognoses. The gene discussed is ERBB2; the disease is neoplasm.